Follow
Tibor Brunt
Tibor Brunt
Senior researcher
Verified email at hetkleineheldenhuis.nl
Title
Cited by
Cited by
Year
Differential regulation of interleukin-10 (IL-10) and IL-12 by glucocorticoids in vitro
J Visser, A van Boxel-Dezaire, D Methorst, T Brunt, ER De Kloet, ...
Blood, The Journal of the American Society of Hematology 91 (11), 4255-4264, 1998
2621998
Instability of the ecstasy market and a new kid on the block: mephedrone
TM Brunt, A Poortman, RJM Niesink, W van den Brink
Journal of psychopharmacology 25 (11), 1543-1547, 2011
2512011
The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects
J Van Amsterdam, T Brunt, W van den Brink
Journal of psychopharmacology 29 (3), 254-263, 2015
2002015
Drug testing in Europe: monitoring results of the Trans European Drug Information (TEDI) project
TM Brunt, C Nagy, A Bücheli, D Martins, M Ugarte, C Beduwe, ...
Drug testing and analysis 9 (2), 188-198, 2017
1702017
A Pro51Ser mutation in the COCH gene is associated with late onset autosomal dominant progressive sensorineural hearing loss with vestibular defects
YJM de Kok, SJH Bom, TM Brunt, MH Kemperman, E van Beusekom, ...
Human molecular genetics 8 (2), 361-366, 1999
1651999
Cross‐sectional and prospective relation of cannabis potency, dosing and smoking behaviour with cannabis dependence: an ecological study
P van der Pol, N Liebregts, T Brunt, J van Amsterdam, R de Graaf, DJ Korf, ...
Addiction 109 (7), 1101-1109, 2014
1332014
An analysis of cocaine powder in the Netherlands: content and health hazards due to adulterants
TM Brunt, S Rigter, J Hoek, N Vogels, P Van Dijk, RJM Niesink
Addiction 104 (5), 798-805, 2009
1262009
Potency trends of Δ9‐tetrahydrocannabinol, cannabidiol and cannabinol in cannabis in the Netherlands: 2005–15
RJM Niesink, S Rigter, MW Koeter, TM Brunt
Addiction 110 (12), 1941-1950, 2015
1232015
Monitoring new psychoactive substances (NPS) in The Netherlands: data from the drug market and the Poisons Information Centre
L Hondebrink, JJ Nugteren-van Lonkhuyzen, D Van Der Gouwe, TM Brunt
Drug and alcohol dependence 147, 109-115, 2015
1182015
Content of ecstasy in the Netherlands: 1993–2008
N Vogels, TM Brunt, S Rigter, P Van Dijk, H Vervaeke, RJM Niesink
Addiction 104 (12), 2057-2066, 2009
1102009
Linking the pharmacological content of ecstasy tablets to the subjective experiences of drug users
TM Brunt, MW Koeter, RJM Niesink, W van den Brink
Psychopharmacology 220, 751-762, 2012
1002012
The Drug Information and Monitoring System (DIMS) in the Netherlands: implementation, results, and international comparison
TM Brunt, RJM Niesink
Drug testing and analysis 3 (9), 621-634, 2011
992011
Drug checking as a harm reduction tool for recreational drug users: opportunities and challenges
T Brunt
European Monitoring Centre for Drugs and Drug Addiction, 2017
872017
Polymorphic detection of a parthenogenetic maternal and double paternal contribution to a 46, XX/46, XY hermaphrodite
JC Giltay, T Brunt, FA Beemer, JM Wit, HKP Van Amstel, PL Pearson, ...
The American Journal of Human Genetics 62 (4), 937-940, 1998
861998
Adverse effects of levamisole in cocaine users: a review and risk assessment
TM Brunt, J van den Berg, E Pennings, B Venhuis
Archives of Toxicology 91, 2303-2313, 2017
752017
Therapeutic satisfaction and subjective effects of different strains of pharmaceutical-grade cannabis
TM Brunt, M van Genugten, K Höner-Snoeken, MJ van de Velde, ...
Journal of clinical psychopharmacology 34 (3), 344-349, 2014
742014
Hallucinogen persisting perception disorder and the serotonergic system: a comprehensive review including new MDMA-related clinical cases
RPW Litjens, TM Brunt, GJ Alderliefste, RHS Westerink
European Neuropsychopharmacology 24 (8), 1309-1323, 2014
732014
Purity, adulteration and price of drugs bought on‐line versus off‐line in the Netherlands
D van der Gouwe, TM Brunt, M van Laar, P van der Pol
Addiction 112 (4), 640-648, 2017
672017
mCPP: an undesired addition to the ecstasy market
MG Bossong, TM Brunt, JP Van Dijk, SM Rigter, J Hoek, HMJ Goldschmidt, ...
Journal of Psychopharmacology 24 (9), 1395-1401, 2010
662010
GHB, GBL and 1, 4-BD Addiction
T M Brunt, J GC van Amsterdam, W van den Brink
Current Pharmaceutical Design 20 (25), 4076-4085, 2014
572014
The system can't perform the operation now. Try again later.
Articles 1–20